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Rapport de synthèse 
Le syndrome métabolique selon différentes définitions dans un pays de la 
région africaine en voie de développement rapide 
Le syndrome métabolique représente un ensemble de facteurs de risque métaboliques souvent 
présents simultanément et il est associé à un risque accru de développer des maladies 
cardiovasculaires. La prévalence du syndrome métabolique est à la hausse au niveau mondial 
comme cela a souvent été documenté, en particulier dans les pays développés. Pourtant, les 
données concernant le syndrome métabolique dans les pays de la région sub-saharienne restent 
rares. 
Au cours des dernières années, plusieurs définitions du syndrome métabolique ont été formulées, 
dont celle du 'National Cholesterol Education Pro gram Adult Treatment Panel III', celle de 
!'Organisation Mondiale de la Santé et celle du 'International Diabetes Federation'. Parmi les 
controverses au sujet du syndrome métabolique persiste la question de l'utilité de rechercher la 
présence du syndrome métabolique chez les patients diabétiques, étant donné que la présence 
d'un diabète en soit suffit pour identifier un individu à haut risque de faire un évènement 
cardiovasculaire. 
L'objectif de ce travail de thèse a été de déterminer la prévalence du syndrome métabolique 
selon les trois définitions majeures mentionnées ci-dessus, grâce à une étude de population 
transversale, réalisée aux Seychelles en 2004 dans un échantillon représentatif de la population 
âgée de 24-65 ans (n=l255, taux de participation de 80.3%). L'intérêt d'examiner cette question 
dans ce pays était d'obtenir des informations dans un pays en transition épidémiologique. 
Les résultats de ce travail montrent que la prévalence du syndrome métabolique aux Seychelles 
est élevée, quelque soit la définition utilisée. Selon la définition utilisée, cette prévalence était 
d'environ 25% chez les hommes et variant entre 25 et 35% chez les femmes. 
Cependant, malgré des prévalences semblables selon ces trois définitions, la concordance entre 
ces définitions n'était pas bonne, impliquant que ces différentes définitions classifient, à un 
certain degré, des individus différents comme étant porteurs du syndrome métabolique. 
En outre, la plupart (environ 80%) des individus diabétiques avaient un syndrome métabolique. 
Après exclusion des individus diabétiques, la prévalence du syndrome métabolique dans la 
population est réduite d'environ un tiers, à environ 20-25%. 
Ces résultats montrent que, d'une part, le fardeau de maladie dû au syndrome métabolique aux 
Seychelles, un pays en voie de développement, est considérable. Cette observation peut 
potentiellement s'appliquer à d'autres pays à un stade de développement semblable. Cela 
renforce le besoin de mettre en œuvre des stratégies de santé publique afin de cibler les causes de 
ces désordres métaboliques, tels que le surpoids et la sédentarité. D'un point de vue du 
diagnostic, les trois définitions du syndrome métabolique semblent classifier un nombre 
semblable de personnes atteints du syndrome métabolique dans cette population. Par contre, la 
relativement mauvaise concordance entre ces définitions - certaines personnes identifiés comme 
porteurs du syndrome métabolique selon une définition ne le sont pas selon une autre - confirme 
la nécessité de clarifier la signification de ces différentes définitions et/ou éventuellement de 
développer une définition unifiée et fiable du syndrome métabolique. 
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Abstract 
Aims: We examined, in a country of the African region, i) the prevalence of the metabolic 
syndrome (MetS) according to three definitions (ATP, WHO and IDF); ii) the distribution of the 
MetS criteria; iii) the level of agreement between these three definitions and iv) we also examined 
these issues upon exclusion of people with diabetes. 
Methods: We conducted an examination survey on a sample representative of the general 
population aged 25-64 years in the Seychelles (lndian Ocean, African region), attended by 1255 
participants (participation rate of 80.3%). 
Results: The prevalence of MetS increased markedly with age. According to the ATP, WHO and 
IDF definitions, the prevalence of MetS was, respectively, 24.0%, 25.0%, 25. I % in men and 32.2%, 
24.6%, 35.4% in women. Approximately 80% of participants with diabetes also had MetS and the 
prevalence of MetS was approximately 7% lower upon exclusion of diabetic individuals. High blood 
pressure and adiposity were the criteria found most frequently among MetS holders irrespective 
of the MetS definitions. Among people with MetS based on any of the three definitions, 78% met 
both ATP and IDF criteria, 67% both WHO and IDF criteria, 54% both WHO and ATP criteria and 
only 37% met ail three definitions. 
Conclusion: We identified a high prevalence of MetS in this population in epidemiological 
transition. The prevalence of MetS decreased by approximately 32% upon exclusion of persons 
with diabetes. Because of limited agreement between the MetS definitions, the fairly similar 
proportions of MetS based on any of the three MetS definitions classified, to a substantial extent, 
different subjects as having MetS. 
Introduction 
The metabolic syndrome (MetS) represents a cluster of 
metabolic risk factors that co-occur to a greater degree 
than predicted by chance. While it is clear that Mets is 
associated with cardiovascular disease and diabetes [ l ], it 
is still controversial whether Mets adds predictive value 
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that go es beyond that of its single constituents [ 1,2]. Insu-
lin resistance was initially the main focus of Mets, but adi-
posity, sedentaiy lifestyle, dietary and genetic factors have 
also received much attention when considering the patho-
genesis of Mets [3]. High prevalence of MetS has often 
been documented in developed countries and increas-
ingly so in developing countries [ 4-1 7], although data in 
developing countries and paiticularly in the Sub-Saharan 
region remain scarce (18]. 
Over the past decade, several definitions of Mets have 
been coined. In this paper, we consider three major defi-
nitions: i) the definition of the World Health Organiza-
tion (WHO), issued in 1998 (19]; ii) the definition of the 
National Cholesterol Education Program Adult Treatment 
Panel III (ATP), issued in 2001 and updated in 2004 and 
2005 (20], and the definition of the International Diabe-
tes Federation (IDF), introduced in 2005 [ 21]. These defi-
nitions agree that the core criteria of Mets include: i) 
blood glucose impairment (hyperglycemia and/or insulin 
resistance), ii) excess abdominal/body fat (increased waist 
and/or obesity), iii) dyslipidemia (low HDL-cholesterol 
and/or high triglycerides ), and iv) elevated blood pres-
sure. However, criteria and eut-off values differ between 
these definitions, implying that different definitions may 
identify different people, as documented in the few stud-
ies that have addressed this question (4, 7,8,22]. 
There is some controversy over whether identification of 
Mets should exclude people with diabetes since diabetes 
alone is sufficient to define high cardiovascular risk and 
Mets has been used as a tool to predict diabetes [2,23]. 
This analysis had four main objectives. First, we evaluated 
the prevalence of Mets according to three Mets definitions 
in the Seychelles, a rapidly developing country of the Afri-
can region. Second, we examined the distribution of the 
Mets criteria according to the different Mets definitions. 
Third, we compared the level of agreement between the 
different MetS definitions and their ability to identify the 
same subjects. Fourth, we examined how the prevalence 
of Mets and the other end points differed upon restricting 
assessment of the metabolic syndrome to the non-dia-
betic population. 
Methods 
Survey procedures 
The Republic of Seychelles is a group of islands in the 
Indian Ocean (African region) situated approximately 
1800 km east of Kenya. A large majority of the population 
is of African descent. HIV and cardiovascular diseases 
account for approximately 1 % and 38% of total mortality, 
respectively (24]. High prevalence of several cardiovascu-
lar risk factors including obesity, hype1tension and diabe-
http://www.cardiab.com/content/7/1/27 
tes has been documented as early as in 1989 [25] and in 
2004 [26-28]. 
A population-based survey of cardiovascular risk factors 
was conducted in 2004 under the auspices of the Minist1y 
of Health of the Republic of Seychelles (Seychelles Heart 
Study III). Methods and main results have been published 
previously (26-28]. Briefly, the sampling frame consisted 
of a sex and age stratified random sample of the entire 
population aged 25-64 years. Eligible participants were 
selected from computerized data of a national population 
census in 2002, thereafter updated by the civil status 
authorities. The survey was approved by the Ministry of 
Health after technical and ethical reviews. Eligible partici-
pants were invited by a letter to attend the smvey at study 
centers on specified dates. They were free to pa1ticipate 
and gave written informed consent. 
Blood pressure was defined as the average of the last two 
of three measurements with a mercmy sphygmomanom-
eter taken at intervals longer than 2 minutes after the par-
ticipants had been sitting for at least 30 minutes. Weight 
was measured with precision electronic scales (Seca, Ham-
burg) and height was measured with a fixed stadiometer. 
Fasting blood was taken between 7:00 and 10:00 am. 
Serum was obtained within 2 hours of blood collection 
and immediately frozen to -20°C. Blood lipids were 
measured with standard methods. Fasting blood glucose 
(FBG) was analyzed immediately with a point-of-care 
analyzer (Cholestec LDX, Hayward, USA). If glucose was 
;:;.: 5.6 mmol/l and the paiticipant was not aware ofhaving 
diabetes, an additional capilla1y measurement was per-
formed within 10 minutes with a glucometer that adjusts 
readings to plasma values (Ascencia Elite, Bayer) and the 
average of the two readings was considered (27]. An oral 
glucose tolerance test (OGTT) was pe1formed on all peo-
ple who had FBG between 5.6 and 7.0 mmol/L but had 
never been diagnosed with diabetes. Fasting serum insulin 
was measured using commercial RIA kits (LINCO 
Research Inc, Missouri, USA). Microalbuminuria was 
measured with a semi-quantitative method using a Cli-
nitek Status analyzer (Bayer, Leverkussen, Germany) [28]. 
Definitions of the metabolic syndrome 
The prevalence of Mets was calculated according to the 
standard criteria detailed in Table 1. For the WHO defini-
tion, we defined insulin resistance as the upper quaitile of 
the homeostasis model assessment of insulin resistance 
(HOMA-IR), calculated as [fasting serum insulin level 
(fnicroU/ml) x fasting blood glucose level (mmol/L)]/ 
22.5 [29], which has been shown to be a reliable estimate 
of insulin resistance both among diabetic and non dia-
betic subjects (30,31 ]. For the IDF definition, we used eth-
nic-specific cutoff values for waist circumference, i.e. the 
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Table 1: Criteria for three definitions of the metabolic syndrome (WHO, ATP, IDF) 
1. Adiposity 
2. Raised blood pressure 
3. Dyslipidemia 
4. lmpaired glucose regulation 
( dysglycemia) 
5. Microalbuminuria 
WHO 1998 
Diabetes, IFG, IGT or insulin 
resistancel 
plus two or more of the remaining 
criteria. 
Waist/hip ratio > 0.9 (M), > 0.85 (F) 
or BMI > 30 kg/m2 
BP 2 140/90 mmHg or medication 
TG 2 1.7 mmol/I or HDL < 0.9 mmol/ 
L (M), < 1.0 mmol/L (F) 
Diabetes, IFG (FBG 2 6.1 mmol/I), 
IGT, or insulin resistancel 
Microalbuminuria: albumin 2 20 µg/ 
min or albumin/creatinine ratio 
(ACR) 2 30 mg/g 
NCEP ATP Ill 2005 
Any three or more criteria. 
IDF 2005 
Central obesity 
plus two or more of the remaining 
criteria. 
WC 2 102 cm (M), 2 88 cm (F) WC 2 94 cm (M), 2 80 cm (f)2 
BP 2 130/85 mmHg or medication 
TG 2 1.7 mmol/L or medicationl 
HDL-C < 1.03 mmol/L (M) or< 1.29 mmol/L (F) or medicationl 
FBG 2 5.6 mmol/L 4 FBG 2 5.6 mmol/L or previously 
diagnosed diabetes 
WHO: World Health Organization [19]; ATP: National Cholesterol Education Program-Adult Treatment Panel Ill [20]; IDF: International Diabetes 
Federation [21 ]. 
BMI: body mass index; BP: blood pressure; HDL-C: high density lipoprotein cholesterol; FBG: fasting blood glucose; IFG: impaired fasting glucose; 
IGT: impaired glucose tolerance; TG: triglycerides; WC: waist circumference. 
1 Glucose uptake below lowest quartile under hyperinsulinemic euglycemic conditions for background population under investigation. 
2 Cut off for Sub Saharan Africans, Europids, and Eastern Mediterranean and Middle Eastern populations; 2 90 cm (M), 2 80 cm (F) for South Asians, 
Chinese, Japanese, and ethnie South and Central Americans [21 ]. 
lSpecific treatment for hypertriglyceridemia or low HDL-cholesterol such as fibrate or nicotinic acid. 
4This eut off was lowered from 2 6.1 mmol/L to 2 5.6 mmol/I in 2005 [20]. 
same criteria for Europid and Sub-Saharan subjects (:2 94 
cm for men and :2 80 cm for women) [21] and, by exten-
sion, for people of 'mixed' descent, and :::: 90 cm for men 
and :2 80 cm for women of the 4% of participants consid-
ered as 'Indian' or 'Chinese'. Information on treatment for 
dyslipidemia was not available at an individual level and 
we assumed that no one was under treatment, consistent 
with the ve1y low number of people treated in Seychelles 
for dyslipidemia. 
Analysis 
Analysis was peiformed with Stata 9.0. All analyses were 
standardized for age using the new WHO standard popu-
lation [32]. Agreement between the three MetS definitions 
was determined using the Kappa statistic (K). We graphed 
Venn diagrams for agreement between different defini-
tions of Mets using the MATLAB 7.6 software, which 
allows representing areas prop01tionally to the corre-
sponding numbers of cases. P values < 0.05 were consid-
ered statistically significant. 
Results 
Characteristics of the population 
From the 1563 eligible pa1ticipants, 1255 participated in 
the smvey (80.3% participation rate) and 1218 had all 
necessary measurements to evaluate Mets according the 
three considered definitions and were included in this 
study. The distribution of selected risk factors and Mets 
criteria is presented in Table 2. 
Prevalence of the metabolic syndrome 
Figure 1 shows the prevalence of Mets according to the 
definitions by ATP, WHO and IDF. The age-standardized 
prevalence of Mets in the population aged 25-64 years 
was 28.1% (95% CI: 25.6-30.7), 24.8% (22.4-27.2) and 
30.3% (27.7-32.9), respectively. At age 35-64, the age-
standardized prevalence was, respectively, 36.7% (33.6-
39.7), 32.4% (29.5-35.4) and 39% (35.9-42.1) overall; 
31.9% (27.5-36.4), 33.4% (28.9-37.9) and 33.5% 
(29.0-38.0) among men; and 41.4% (37.1-45.6), 31.4% 
(27.5-35.4) and 44.4% ( 40.2-48.7), among women. 
The prevalence of MetS increased markedly with age for 
both genders. However, the prevalence of MetS using the 
ATP definition was highest at age 45-54 for men. With 
regards to gender, the prevalence was significantly greater 
in women than in men according to the ATP and IDF def-
initions while the prevalence was similar in both genders 
using the WHO definition. 
A large prop01tion of people with diabetes also had MetS: 
66.8%, 85.5%, 74% amongmen and 87.1%, 79.7%, 93% 
among women, according to the ATP, WHO and IDF def-
initions, respectively. However, this proportion was 
sihaller among men at age 45-64 years than in the other 
age categories (Figure 1). 
Upon exclusion of individuals with diabetes, the age-
standardized prevalence of MetS at age 25-64 years was 
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Table 2: Age-standardized distribution of selected risl< factors in the population aged 25-64 years 
Ali SD Men SD Women SD 
N 1218 548 679 
Age (years) 42.0 10.8 42.1 10.7 41.9 11.0 
Anthropometric parameters 
BMI (kg/m2) 26.9 5.7 25.5 4.7 28.3 6.3 
Waist circumference (cm) 89.5 13.0 88.9 11.9 90.2 14.1 
Adiposity ATP (%) WC 2 102 cm (M), 2 88 cm (W) 35.2 14.0 56.0 
WHR > 0.9 (M), > 0.85 (W) or BMI 61.5 50.7 72.1 
Adiposity WHO (%) > 30 
Adiposity IDF (%) WC 2 94 cm (M), 2 80 cm (W) 55.8 35.8 75.6 
Blood pressure 
Systolic BP (mmHg) 127.7 18.6 131.0 17.7 124.4 18.8 
Diastolic BP (mmHg) 83.3 11.8 85.5 11.7 81.2 11.5 
Raised BP-ATP/IDF (%) BP 2 130/85 mmHg or medication 51.7 57.0 46.4 
Raised BP - WHO (%) BP 2 140/90 mmHg or medication 39.5 43.3 35.7 
Glucose regulation 
Fasting glucose (mmol/L) 5.9 2.0 6.0 2.1 5.7 1.8 
lnsulin (pmol/L) 14.8 12.1 13.6 11.6 16.1 12.4 
lmpaired fasting glucose (%) 14.1 20.5 7.7 
lmpaired glucose tolerance (%) 12.6 13.9 11.2 
Diabetes (%) 10.7 9.7 11.7 
Dysglycemia A TP (%) FBG 2 5.6 mmol/I 33.3 40.0 26.7 
Dysglycemia WHO (%) DM, IFG, IGT or insulin resistance 36.1 35.5 36.7 
Dysglycemia IDF (%) FBG 2 5.6 mmol/I or history of DM 33.9 40.4 27.5 
Blood lipids 
Total cholesterol (mmol/L) 5.4 1.3 5.4 1.3 5.4 1.3 
HDL cholesterol (mmol/L) 1.4 0.5 1.4 0.5 1.4 0.4 
Triglyceride level (mmol/L) 1.0 0.8 1.2 1.0 0.9 0.5 
Hypertriglyceridemia A TP/IDF (%) TG 2 1.7 mmol/I or medication 12.6 17.4 7.8 
Low HDL-C ATP/IDF (%) HDLC < 1.03 (M); < 1.29 (W) 38.2 28.6 47.8 
Dyslipidemia WHO (%) TG 2 1.7 or HDL < 0.9 (M), < 1.0 (W)) 23.8 27.3 20.3 
Microalbuminuria 11.9 11.2 12.6 
Regular cigarette smoking (%) 17.3 30.9 3.7 
Alcohol (mUday) 22.3 62.0 41.1 82.8 3.6 12.8 
Mean ± SD (standard deviation) or proportion; BMI: body mass index; WC: waist circumference; WHR: waist to hip ratio; BP: blood pressure; DM: 
diabetes; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; M: men; W: women. HDL-cholesterol and triglyceride: units in mmol/L. 
22.2% (19.6-24.7} according to ATP, 17.9% (15.6-20.2} 
according to WHO and 23.8% (21.2-26.4} according to 
IDF. Using the EGIR definition of MetS (33], a modified 
version of the WHO definition that applies to non-dia-
betic subjects, the age-standardized prevalence of Mets 
was 15.1% (95% CI: 12.9-17.3}; 14.1% (10.9-17.2} 
among men and 16.2% (13.1-19.2} among women. 
Upon exclusion of persans with diabetes, the prevalence 
(in absolute terms) of MetS decreased by 4.6%, 6.5%, 
5.3% in men and 7.3%, 7.3%, 7.7% in women according 
to the ATP, WHO and IDF definitions, respectively. This 
corresponds to a relative decrease in the prevalence of 
MetS of approximately 32%. At the age of35-64 years, the 
decrease in prevalence (in absolute terms) was respec-
tively 5.8%, 8.6%, 6.7% in men and 7.8%, 6.7%, 8.8% in 
women (a relative decrease of approximately 34%). The 
reduction in prevalence of MetS upon exclusion of sub-
jects with diabetes was slightly greater when using the 
WHO definition of Mets than the other two definitions. 
Distribution of criteria of the metabolic syndrome 
High blood pressure, obesity and impaired glucose regu-
lation were the most prevalent criteria for all Mets defini-
tions (Figure 2}. Hypertriglyceridemia was found more 
often in men than in women, while the opposite was tme 
for low HDL-cholesterol. This criteria distribution was 
similar across age categories. 
Agreement between different definitions of the metabolic 
syndrome 
Figure 3 shows the level of agreement between the three 
Mets definitions. 37% of all subjects aged 25-64 had 
Mets as based on any of the three Mets definitions. 
Among these MetS-holders, 69% had Mets based on ATP 
and IDF, 50% based on ATP and WHO, 53% based on 
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Men 
80 25-34 35-44 45-54 55-64 Total 
70 D Mets without diabetes 
60 D Mets with diabetes 
50 D Diabetes without Mets 43 ~ 37 37 37 39 ~ 40 Q) 32 0 28 27 21 c 30 Q) 22 24.0 25 .0 25 .1 
ëij 27 26 27 19 > 20 ~ 21 18 20 17 18 Cl.. 18 
10 7 7 7 22 
11 13 17 7 7 7 10 10 6 7 0 
1 
10 9 
20 13 
ATP WHO IDF ATP WHO IDF ATP WHO IDF ATP WHO IDF ATP WHO IDF 
Women 25-34 35-44 
80 
45-54 55-64 Total 
70 D Mets without diabetes 68 63 D Mets with diabetes 58 60 
D Diabetes without Mets 
50 45 46 36 
~ 31 27 ~ 40 35.4 Q) 29 30 32.2 0 
c 30 27 32 33 24.6 Q) 
ëij 25 > 20 15 17 19 22 ~ 24 Cl.. 
10 
11 
0 
10 4 3 
20 
ATP WHO IDF ATP WHO IDF ATP WHO IDF ATP WHO IDF ATP WHO IDF 
Figure 1 
Prevalence of the metabolic syndrome according to sex, age category, diabetic status and different definitions 
of the metabolic syndrome. 
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Proportion of subjects with the metabolic syndrome who have selected criteria according to sex and different 
definitions of the metabolic syndrome (TG: triglyceride; HDL: HDL-cholesterol; BP: blood pressure). 
WHO and IDF; and 48% had MetS based on the three def-
initions . With reference to the total population, MetS was 
diagnosed in 28% based on ATP, 25% based on WHO and 
30% based on IDF. Based on Figure 3, one can calculate 
that 25% were diagnosed with MetS based on ATP and 
IDF, 20% based on WHO and IDF, 19% based on WHO 
and ATP; and 18% based on al! three definitions. 
Within the non-diabetic population, 30% had MetS based 
on either the WHO, ATP or IDF definitions, out of which 
3 7% had MetS based on al! three definitions. 
The kappa statistic was 0.82 for ATP-IDF, 0.61 for IDF-
WHO and 0.59 for WHO-ATP, respectively 0 .81, 0 .53 and 
0 .5 1, upon exclusion of people with diabetes. The higher 
kappa statistic for ATP-IDF versus either IDF-WHO or 
WHO-ATP was found irrespective of gender and age 
(Table 3) . 
In order to examine possible causes of fairly low agree-
ment between the Mets definitions, we compared agree-
ment between the oiteria of the three MetS definitions in 
the entire population (Table 4). The largest disagreement 
was found for adiposity. As many as 70% of the total pop-
ulation fulfilled the criteria for adiposity according to 
either the ATP, WHO or IDF definitions of Mets (i .e. 
based on BMI, waist circumference or waist to hip ratio). 
However, the prevalence of the adiposity crite1ion varied 
largely according to the different MetS definitions: 35.2% 
according to ATP, 61.5% according to WHO, and 55.8% 
according to IDF. Out of those who qualified for adiposity 
according to any MetS definitions, only 48% met ail three 
definitions . With regards to the other MetS crite1ia, the 
WHO definition disagreed with the other two definitions 
of Mets (ATP and IDF) in identifying people with dyslip-
idemia and to a lesser extent, with impaired glucose regu-
lation. However, these criteria are Jess prevalent in the 
population than adiposity (Table 2), which results in less 
impact on MetS classification. 
Discussion 
The main findings of the study are as follows: i) the prev-
alence of MetS was high in this population of East Africa 
regard Jess of which MetS definition was used; ii) the prev-
alence of Mets decreased by approximately one third 
upon exclusion of persans with diabetes; and iii) agree-
ment between different MetS definitions was limited and 
consequently, the similar prevalence of MetS according to 
either MetS definition actually identified, to a substantial 
extent, different subjects as having Mets. 
In our study, the prevalence of Mets at the age of 25-64 
years ranged between 25% and 30%. This is much higher 
than the 8% repo1ted in Cameroon (18], which is, to the 
best of our knowledge, the only other population based 
published assessment of the prevalence of MetS in Sub-
Saharan Africa. A previous study in the Seychelles [ 34] 
found that plasma aldosterone, but not plasma renin 
activity, was associated with MetS. However this study 
included participants from families with hypertension 
and was therefore not intended to assess the prevalence of 
MetS in the general population . In order to compare the 
prevalence in Seychelles with that in other countries, we 
compiled findings of selected population-based studies 
that had assessed Mets according to at least two Mets def-
initions, and included participants of 35-64 years (Table 
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Total population 
Figure 3 
ATP 
24% 
No Mets: 65% 
ATP 
No Mets: 63% 
Men 
IDF 
25% 
IDF 
30% 
No Mets: 61% 
WHO 
25% 
Women 
35% 
WHO 
25% 
Agreement between three definitions of the metabolic syndrome (all prevalence estimates are expressed as 
percent of the general population). 
5). The prevalence of MetS was similar in Seychelles as in 
many Western countlies [9-11,13) and in urban India 
[ 15). The prevalence of MetS in Seychelles was lower than 
in certain countries, e.g. USA [5], Portugal [8), Samoa 
[ 13], Turkey [7] and Tunisia [4] but higher than in Mexico 
[6) and several Asian countries e.g. Korea [14], Japan [13] 
and China [ 1 7). The high prevalence of MetS in Seychelles 
is consistent with high prevalence of several MetS criteria, 
particularly overweight, hypertension, dyslipidemia and 
diabetes (25-27) . 
The prevalence of MetS in Seychelles did not differ mark-
edly according to the three different MetS definitions, con-
sistent with observations in several populations 
[5,9,10,14,17], but not in others [4-7,12,13] . However, 
the prevalence of MetS in Seychelles was moderately 
higher according to IDF than ATP or WHO, a finding 
repmted in most studies that had assessed this issue 
(4,5,7,8,10-13,15] , except for a few [16,17). It has fre-
quently been repmted that the prevalence of MetS accord-
ing to the WHO definition is generally greater among men 
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Table 3: Agreement (kappa values) between different definitions of the metabolic syndrome in the population with and without 
exclusion of diabetic persons 
ATP-IDF 
Ali Non-diabetic 
Ali 0.82 0.81 
Men 0.71 0.67 
Women 0.92 0.91 
Age 25-44 years 0.79 0.76 
Age 45-64 years 0.83 0.83 
than women [35] but we did not obseive such a gender 
difference in Seychelles. 
The level of agreement between the different definitions 
of Mets was not optimal in our study. Less than half of the 
individuals labeled as having MetS according to any of the 
three considered definitions were dassified as MetS-hold-
ers according to ail three definitions. We found that agree-
ment between the MetS definitions was better for IDF-ATP 
than for WHO-IDF and WHO-ATP. This finding is consist-
ent with data in several populations on several continents 
[7,8,10,13,15]. This difference is expected since MetS is 
based on the same criteria according to IDF and ATP, 
except for the adiposity criterion. Agreement between the 
MetS definitions was generally better among women than 
men in Seychelles, cons istent with previous repo11s 
[5,8,14] . This may relate to the fact, at least in Seychelles, 
that the prevalence of the adiposity criterion was virtually 
identical and close to 100% across the three MetS defini-
tions among women with MetS, but was lower and largely 
different between Mets definitions in men. 
Table 4: Kappa values between different criteria of different 
definitions of the metabolic syndrome 
ATP-IDF IDF-WHO WHO-ATP 
Total population 
Obesity 0.60 0.55 0.44 
Raised blood pressure 1.00 0.76 0.76 
lmpaired glucose regulation 0.99 0.67 0.66 
Hypertriglyceridemia 1.00 1.00 1.00 
Low HDL-cholesterol 1.00 0.50 0.50 
Men 
Obesity 0.45 0.55 0.27 
Raised blood pressure 1.00 0.73 0.73 
lmpaired glucose regulation 0.99 0.65 0.64 
Hypertr iglyceridemia 1.00 1.00 1.00 
Low HDL-cholesterol 1.00 0.69 0.69 
Women 
Obesity 0.58 0.45 0.50 
Raised blood pressure 1.00 0.78 0.78 
lmpaired glucose regulation 0.98 0.70 0.68 
Hypertriglyceridemia 1.00 1.00 1.00 
Low HDL-cholesterol 1.00 0.36 0.36 
IDF-WHO WHO-ATP 
Ali Non-diabetic Ali Non-diabetic 
0.61 0.53 0.59 0.51 
0.62 0.55 0.56 0.48 
0.60 0.52 0.63 0.53 
0.49 0.42 0.52 0.44 
0.64 0.58 0.58 0.53 
Hence, we found a similar prevalence of MetS in Sey-
chelles according to the three different MetS definitions 
but the different Mets definitions actually identified, to a 
substantial extent, different individuals. Poor agreement 
between MetS definitions has several clinicat and epide-
miological implications [ 16,22]. First, it is questionable to 
directly compare the burden of MetS between populations 
based on different definitions . Second, it remains unclear 
whether cardiometabolic outcomes differ if MetS is 
defined according to one, two or three Mets definitions. 
Few studies have assessed the predictive value of MetS 
when MetS is based on more than one definition [36] . The 
study of Benetos et al [36] showed that the prevalence of 
Mets was markedly higher when MetS was based on either 
the IDF or ATP (2005 version) definitions as compared to 
the 2001 ATP definition atone, but only individuals with 
MetS according to the 2001 ATP definition had a higher 
risk of ail-cause and cardiovascular mortality. 
The prevalence of Mets restricted to the non-diabetic pop-
ulation ( e.g. according to the EGIR definition, which is a 
definition of Mets that explicitly excludes diabetes [33]) 
was similar in Seychelles as in several countries in Europe 
[37-39] and higher than in Japan and Korea [13] . In the 
Seychelles, about one third of the adults who had MetS 
also had diabetes and, inversely, most adults who had dia-
betes also had MetS. Hence, the prevalence of MetS, 
according to either the ATP, WHO and IDF definitions, 
decreased markedly (a relative decrease of approximately 
one third) upon exclusion of persons with diabetes. This 
difference is larger than reported in other studies [ 6, 13]. 
We also obse1ved that this decrease in the prevalence of 
MetS upon exclusion of diabetes was larger according to 
the WHO definition compared to the ATP and IDF defini-
tions, which has also been obseived in Samoa [ 13] and 
Mexico [6] . 
T[ie issue of whether Mets should be defined upon exclu-
sion of diabetes is relevant to both clinical practice and 
epidemiology. It has been argued that MetS status does 
not add incremental info1mation for cardiovascular man-
agement of diabetic individuals [ 23 ], sin ce diabetes al one 
defines high cardiovascular risk. For the same reason, it 
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Table 5: Prevalence of the metabolic syndrome in the Seychelles and in other populations, according to different definitions of the 
metabolic syndrome 
ATP WHO IDF 
Place Population Age n M w Ali M w Ali M w Ali 
Africa 
Seychelles Nation wide 25--64 1218 24 32 28 25 25 25 25 35 30 
Tunisia [3] City of Tunis ~ 40 863 15 31 24 26 31 29 30 56 46 
Cameroon[ 17] City of Yaoundé and three rural villages 24-74 1573 < 0.5 < 0.2 <8 <6 <2 < 2 
Americas 
USA [4] NHANES 1999-2002 ~ 20 3601 34 35 35 41 37 39 
Mexico (5] Nation wide 20--69 2158 29 25 27 13 14 14 
Europe 
Turkey (6] Istanbul (urban) and Kayseri (rural) > 20 1568 41 43 38 23 18 19 46 48 42 
Portugal [7] City of Porto 18-92 1433 32 40 37 30 24 26 38 44 42 
Canary Island [8] Nation wide > 30 1030 28 29 28 33 24 28 
Norway [9] North-Trondelag Health Study (HUNT 2) 20--89 10,206 27 25 26 29 30 30 
Germany [ 1 O] PROCAM study 16--65 7131 25 18 32 23 
Greece (11] Representative sample of Greek adults > 18 9,669 25 24 25 43 
Asia 
Samoa (12] Population-based (DETECT 2) > 35 1344 39 57 22 26 45 60 
Australia [ 12] Population-based (DETECT 2) > 35 9409 36 28 26 18 42 33 
Korea (13] Korean National Health and Nutrition Survey ~ 20 6601 18 21 19 15 24 20 
lndia (14] City of Chennai ~ 20 2350 17 19 18 27 20 23 23 28 26 
Taiwan (15] Taiwan National Nutrition and Health Survey ~ 19 2608 12 17 6 13 
Japan (12] Population-based (DETECT 2) > 35 2016 8 10 8 11 
China (16] Two agricultural counties 25--64 18,630 5 12 8 4 11 7 
Men: men; W: women, ATP: National Cholesterol Education Program-Adult Treatment Panel Ill; WHO: World Health Organization, IDF: 
International Diabetes Federation. 
has been suggested that the definition of MetS should 
exclude individuals with known cardiovascular disease 
(23]. The question ofwhether MetS should exclude diabe-
tes and/or cardiovascular disease is clearly dependent on 
the expected purpose of MetS, i.e. whether Mets is used to 
predict cardiovascular diseases, diabetes, insulin resist-
ance, or a combination of these conditions independent 
of conventional 1isk factors. While our cross-sectional 
study emphasizes that different definitions of MetS tend 
to classify different individuals as having Mets, the most 
impo11ant question remains to determine, based on lon-
gitudinal data, whether MetS predicts cardiovascular 
events above the risk factors that constitute the syndrome. 
Our study has some limitations. First, we cannot exclude 
a healthy volunteer bias related to voluntary pa11icipation 
to the study, which could tend to underestimate the actual 
prevalence of MetS in the population. Second, we assessed 
insulin resistance based on HOMA-IR, which is only par-
tially correlated with the gold standard (hyperinsulinemic 
euglycemic clamp), yet a valid proxy for insulin resistance 
(30,31 ]. Third, OGTT was only pe1formed on participants 
unaware of having diabetes and who had FBG between 
5.6 and 7.0 mmol/l, hence a source of slight underestima-
tion of diabetes . On the other hand, strengths of the study 
include the population-based design of the study, a fairly 
large sample size, and a broad panel of investigations that 
allowed us to directly compare the different MetS defini-
tions . 
In conclusion, this study con tri butes to mapping the prev-
alence of MetS worldwide, particularly with regards to the 
African region. The study also further contributes to the 
longstanding debate regarding the significance of MetS. 
The substantially different prevalence of MetS upon exclu-
sion of individuals with diabetes underlies the need to 
clarify whether MetS is a tool for predicting cardiovascular 
disease, diabetes, insulin resistance or any other risk con-
dition. These issues are further prompted by the finding, 
in our study, that the different considered Mets defini-
tions identified, to a substantial extent, different individ-
uals. Not withstanding a much needed unified definition 
of MetS, our findings in Seychelles emphasize the growing 
burden of lifestyle-related non-communicable diseases in 
countries in epidemiological transition including in the 
African region, consistent with the ongoing epidemic of 
oJ:>esity worldwide and in the Seychelles in particular. 
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